- Previous Close
1.280 - Open
1.250 - Bid 1.230 x --
- Ask 1.250 x --
- Day's Range
1.210 - 1.250 - 52 Week Range
0.470 - 1.810 - Volume
50,000 - Avg. Volume
857,844 - Market Cap (intraday)
2.53B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
∞ - EPS (TTM)
0.000 - Earnings Date Mar 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.12
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services. The company also provides early stage clinical/bioequivalence services; absolute bioavailability and human radiolabel studies; and chemistry services, including performing custom synthesis. It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Co., Limited.
www.frontagelab.comRecent News: 1521.HK
View MorePerformance Overview: 1521.HK
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1521.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1521.HK
View MoreValuation Measures
Market Cap
2.53B
Enterprise Value
3.39B
Trailing P/E
401.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.28
Price/Book (mrq)
0.98
Enterprise Value/Revenue
1.71
Enterprise Value/EBITDA
35.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.31%
Return on Assets (ttm)
0.88%
Return on Equity (ttm)
0.18%
Revenue (ttm)
254.91M
Net Income Avi to Common (ttm)
791k
Diluted EPS (ttm)
0.000
Balance Sheet and Cash Flow
Total Cash (mrq)
44.09M
Total Debt/Equity (mrq)
46.18%
Levered Free Cash Flow (ttm)
15.73M